Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 487, Issue 4, Pages 820-826Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2017.04.133
Keywords
Brusatol; Pancreatic cancer; Apoptosis; JNK/p38 MAPK/NF-kappa b/Stat3/BcI-2
Categories
Funding
- National Natural Science Foundation of China [81370563, 81570583]
- Outstanding Youth Fund of Zhejiang Province [LR14H30001]
- Health and Family Planning Commission of Zhejiang Province [2013ZDA014]
Ask authors/readers for more resources
Brusatol, isolated from brucea, has been proved to exhibit anticancer influence on various kind of human malignancies. However, the role that brusatol plays in pancreatic cancer is seldom known by the public. Through researches brusatol was proved to inhibit growth and induce apoptosis in both PATU-8988 and PANC-1 cells by decreasing the expression level of Bcl-2 and increasing the expression levels of Bax, Cleaved Caspase-3. Then we found the activation of the JNK, p38 MAPK and inactivation of the NF-kappa b, Stat3 are related with the potential pro-apoptotic signaling pathways. However, SP600125 could not only abrogated the JNK activation caused by brusatol, but also reverse the p38 activation and the decrease of BcI-2 as SB203580 did. Besides, SP600125 and SB203580 also reversed the inactivation of NF-kappa b and Stat3. Furthermore, BAY 11-7082 and S3I-201 indeed had the similar effect as brusatol had on the expression of Phospho-Stat3 and Bcl-2. To sum up, we came to a conclusion that in pancreatic cancer, brusatol do inhibit growth and induce apoptosis. And we inferred that brusatol illustrates anticancer attribution via JNK/p38 MAPK/NF-kappa b/Stat3/Bc1-2 signaling pathway. (C) 2017 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available